Literature DB >> 17453166

[Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)].

F Lordick1, J R Siewert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 17453166     DOI： 10.1007/s00104-007-1340-6

Source DB:  PubMed          Journal:  Chirurg        ISSN： 0009-4722            Impact factor:   0.955


× No keyword cloud information.
  22 in total

Review 1.  Regulation of angiogenesis via vascular endothelial growth factor receptors.

Authors:  T Veikkola; M Karkkainen; L Claesson-Welsh; K Alitalo
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

2.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

3.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.

Authors:  Lee M Ellis; Steven A Curley; Axel Grothey
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

4.  Neoadjuvant therapy with bevacizumab.

Authors:  Thomas Gruenberger; Birgit Gruenberger; Werner Scheithauer
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

Review 5.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 6.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

7.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Authors:  L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

10.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
View more
  1 in total

1.  [Developments in modern oncology. Ramifications for anesthesia and intensive care medicine].

Authors:  B Alt-Epping; S Alt-Epping; M Quintel; F Nauck
Journal:  Anaesthesist       Date:  2009-08       Impact factor: 1.041
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.